CRISPR Therapeutics and KSQ Therapeutics Cross Licenses their IP Rights to Facilitate Cell Therapy Programs in Oncology

CRISPR Therapeutics and KSQ Therapeutics Cross Licenses their IP Rights to Facilitate Cell Therapy Programs in Oncology

Shots:

  • CRISPR to gain access to KSQ intellectual property (IP) for editing certain novel gene targets in its allogeneic oncology cell therapy programs while KSQ will get access to CRISPR’ IP for its autologous cell therapies including its existing eTIL cell franchise
  • The agreement allows KSQ to leverage CRISPR’s editing technology in its eTIL programs, involves editing gene targets in human TILs by utilizing its CRISPRomics approach to immune cells in multiple in vivo models. CRISPR to get an opportunity to strengthen its future program in oncology
  • KSQ’s CRISPRomics drug discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas while CRISPR/Cas9 is a revolutionary gene-editing technology allowing precise & directed changes to genomic DNA

Click here to­ read full press release/ article | Ref: CRISPR | Image: The Motley Fool